Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features

Pancreas

Volumn 41, Issue 2, 2012, Pages 206-211

  Zhao, Ling ^a   Cui, Quancai ^a   Lu, Zhaohui ^a   Chen, Jie ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

hypermethylation; pancreatic ductal adenocarcinoma; RASSF2A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RAS PROTEIN; RASSF2A PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CHINA; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84857917376     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318223d1a5     Document Type: Article

References (27)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689. (Pubitemid 19213607)
2. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-1734. (Pubitemid 27199667)
3. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol. 2007;34:303-310. (Pubitemid 47176618)
4. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128:683-692. (Pubitemid 46273572)
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054. (Pubitemid 37448928)
6. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835-1839. (Pubitemid 30207640)
7. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 2002;160: 1573-1581. (Pubitemid 34525637)
8. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006;13:286-295. (Pubitemid 44111336)
9. Sato N, Fukushima N, Hruban RH, et al. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol. 2008;21:238-244. (Pubitemid 351304281)
10. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 2001;61:8540-8546. (Pubitemid 33131137)
11. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006;27:1160-1168. (Pubitemid 43985431)
12. Spandidos DA, Sourvinos G, Tsatsanis C, et al. Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int J Oncol. 2002;21:237-241.
13. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114-128.
14. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene. 2005;24:3987-3994. (Pubitemid 40896410)
15. Vos MD, Ellis CA, Elam C, et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003;278: 28045-28051. (Pubitemid 36900001)
16. Akino K, Toyota M, Suzuki H, et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology. 2005;129:156-169. (Pubitemid 41002052)
17. Maruyama R, Akino K, Toyota M, et al. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis. 2008;29:1312-1318.
18. Kaira K, Sunaga N, Tomizawa Y, et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol. 2007;31:169-173.
19. Zhang Z, Sun D, Van do N, et al. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer. 2007;120:32-38. (Pubitemid 44901914)
20. Lü ttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191:154-161. (Pubitemid 30394893)
21. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826. (Pubitemid 26296693)
22. Imai T, Toyota M, Suzuki H, et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci. 2008;99:958-966. (Pubitemid 351997598)
23. Park HW, Kang HC, Kim IJ, et al. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer. 2007;120:7-12.
24. Endoh M, Tamura G, Honda T, et al. RASSF2, a potential tumor suppressor, is silenced by CpG sland hypermethylation in gastric cancer. Br J Cancer. 2005;93:1395-1399. (Pubitemid 41752867)
25. Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008;123:296-302. (Pubitemid 351842013)
26. Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998;58:5489-5494. (Pubitemid 28551135)
27. Smiraglia DJ, Rush LJ, Frühwald MC, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet. 2001;10:1413-1419. (Pubitemid 32640670)